Clinical Trials Logo

Clinical Trial Summary

Given the need for a more sensitive pathogen detection test in patients with immunocompromised pneumonia, this study will evaluate the performance of the Karius Test, a novel NGS blood test for the diagnosis of infectious diseases. We will compare the performance of the Karius Test to the results of microbiologic tests obtained as part of usual care for immunocompromised patients undergoing evaluation for suspected pneumonia.


Clinical Trial Description

Pneumonia is a major cause of morbidity and mortality in highly immunocompromised individuals such as patients with hematologic malignancies and/or hematopoietic stem cell transplant. These patients can be infected by a broad range of potential pathogens, including viral, bacterial, and fungal etiologies and sometimes with multiple pathogens simultaneously. Diagnostic testing often fails to identify a microbial etiology for lower respiratory illness even with bronchoalveolar lavage (BAL). In fact, culture methods, PCR, and antigen testing on BAL samples yields a positive result only 30-67% of the time. Additionally, Idiopathic Pulmonary Syndrome (IPS), a non-infectious pulmonary complication of transplant, can have many overlapping symptoms with infectious pneumonia. Treatment for IPS is administration of steroids which can exacerbate infections. Given these reasons, there is a need for better diagnostics to aid in the management of immunocompromised patients with pneumonia. Karius has developed a microbial cell-free plasma next-generation sequencing test for pathogen detection capable of detecting >1,000 organisms including DNA viruses, bacteria, yeasts, molds, and other eukaryotic pathogens. The test is performed in a CLIA-certified/CAP-accredited laboratory with results typically provided within one day from sample receipt. Given the need for a more sensitive diagnostic test for pneumonia in this population, we are evaluating the performance of the Karius Test for pathogen detection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04047719
Study type Observational
Source Karius, Inc.
Contact
Status Completed
Phase
Start date November 5, 2019
Completion date June 6, 2022

See also
  Status Clinical Trial Phase
Completed NCT04517123 - Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study N/A
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Completed NCT01271842 - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study N/A
Completed NCT04724538 - Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19 Phase 1/Phase 2
Recruiting NCT04414293 - Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis N/A
Recruiting NCT04528888 - Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Phase 3
Completed NCT04606407 - Inhaled NO for the Treatment of Viral Pneumonia in Adults N/A
Terminated NCT04619693 - Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
Recruiting NCT05077917 - Cromolyn Sodium for Treatment of COVID-19 Pneumonia Phase 3
Withdrawn NCT04381923 - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia N/A
Recruiting NCT05976581 - Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients N/A
Active, not recruiting NCT04381364 - Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) Phase 2
Completed NCT04422613 - Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia N/A
Completed NCT04479540 - Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease N/A
Recruiting NCT04474340 - COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients Phase 1
Completed NCT04424836 - HFNC Treatment in COVID-19 Pneumonia
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT04387799 - Determinants of COVID-19 Pneumonia (MC-19)
Completed NCT04382547 - Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Phase 1/Phase 2
Recruiting NCT04399681 - The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 N/A